NVDA vs SMCI

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.

SMCI exhibits a critical divergence between explosive top-line growth and deteriorating fundamental health, highlighted by a weak Piotroski F-Score of 3/9. While the stock appears undervalued on a PEG (0.91) and Price/Sales (0.61) basis, the defensive Graham Number of $18.97 suggests the current price of $28.56 is unsupported by tangible assets and earnings stability. Severe margin compression is evident as revenue growth (123.4%) vastly outpaces earnings growth (19.2%), and a 0/100 technical trend combined with bearish insider activity signals a lack of confidence in the short-term recovery.